Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

10.0%

1 terminated/withdrawn out of 10 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

10%

1 trials in Phase 3/4

Results Transparency

0 of 6 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 2

8(80.0%)

N/A

1(10.0%)

Phase 3

1(10.0%)

10Total

Phase 2(8)

N/A(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT07121322Phase 2Recruiting

Dornase Alfa and Cisplatin in Refractory Germ Cell Cancer.

Role: lead

NCT04691284Not ApplicableRecruiting

Microbiome in Cancer Patients With High Dose Chemotherapy With Stem Cell Transplantation

Role: lead

NCT04265274Phase 2Withdrawn

Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.

Role: lead

NCT03950830Phase 2Completed

Disulfiram and Cisplatin in Refractory TGCTs.

Role: lead

NCT02819960Phase 3Completed

Prevention of Irinotecan Induced Diarrhea by Probiotics

Role: collaborator

NCT03617133Phase 2Recruiting

Image Guided IMRT, Radiochemotherapy and MRI-based IGABT in Locally Advanced Cervical Cancer

Role: collaborator

NCT02860819Phase 2Completed

Study of Gemcitabine, Carboplatin and VELIPARIB (ABT-888) in Refractory Testicular Germ Cell Cancer

Role: lead

NCT02414685Phase 2Completed

First Line TIP in Poor Prognosis TGCTs.

Role: lead

NCT03403777Phase 2Completed

Avelumab in Refractory Testicular Germ Cell Cancer.

Role: lead

NCT01466231Phase 2Completed

Everolimus in Refractory Testicular Germ Cell Cancer

Role: lead

All 10 trials loaded